Literature DB >> 12368906

Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis.

Richard Sharp1, Juan A Recio, Chamelli Jhappan, Toshiyuki Otsuka, Shiquan Liu, Yanlin Yu, Wenjing Liu, Miriam Anver, Fariba Navid, Lee J Helman, Ronald A DePinho, Glenn Merlino.   

Abstract

Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma in children, yet molecular events associated with the genesis and progression of this potentially fatal disease are largely unknown. For the molecules and pathways that have been implicated, genetic validation has been impeded by lack of a mouse model of RMS. Here we show that simultaneous loss of Ink4a/Arf function and disruption of c-Met signaling in Ink4a/Arf(-/-) mice transgenic for hepatocyte growth factor/scatter factor (HGF/SF) induces RMS with extremely high penetrance and short latency. In cultured myoblasts, c-Met activation and Ink4a/Arf loss suppress myogenesis in an additive fashion. Our data indicate that human c-MET and INK4a/ARF, situated at the nexus of pathways regulating myogenic growth and differentiation, represent critical targets in RMS pathogenesis. The marked synergism in mice between aberrant c-Met signaling and Ink4a/Arf inactivation, lesions individually implicated in human RMS, suggests a therapeutic combination to combat this devastating childhood cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12368906     DOI: 10.1038/nm787

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  62 in total

Review 1.  Advances in pediatric rhabdomyosarcoma characterization and disease model development.

Authors:  D O'Brien; A G Jacob; S J Qualman; D S Chandler
Journal:  Histol Histopathol       Date:  2012-01       Impact factor: 2.303

2.  Macrophage migration inhibitory factor is secreted by rhabdomyosarcoma cells, modulates tumor metastasis by binding to CXCR4 and CXCR7 receptors and inhibits recruitment of cancer-associated fibroblasts.

Authors:  Maciej Tarnowski; Katarzyna Grymula; Rui Liu; Joanna Tarnowska; Justyna Drukala; Janina Ratajczak; Robert A Mitchell; Mariusz Z Ratajczak; Magda Kucia
Journal:  Mol Cancer Res       Date:  2010-09-22       Impact factor: 5.852

3.  Zebrafish models of rhabdomyosarcoma.

Authors:  Eleanor Y Chen; David M Langenau
Journal:  Methods Cell Biol       Date:  2011       Impact factor: 1.441

4.  A pan-inhibitor of DASH family enzymes induces immune-mediated regression of murine sarcoma and is a potent adjuvant to dendritic cell vaccination and adoptive T-cell therapy.

Authors:  Brynn B Duncan; Steven L Highfill; Haiying Qin; Najat Bouchkouj; Shannon Larabee; Peng Zhao; Iwona Woznica; Yuxin Liu; Youhua Li; Wengen Wu; Jack H Lai; Barry Jones; Crystal L Mackall; William W Bachovchin; Terry J Fry
Journal:  J Immunother       Date:  2013-10       Impact factor: 4.456

5.  Ezrin mediates both HGF/Met autocrine and non-autocrine signaling-induced metastasis in melanoma.

Authors:  Liping Huang; Yifei Qin; Qiang Zuo; Kavita Bhatnagar; Jingbo Xiong; Glenn Merlino; Yanlin Yu
Journal:  Int J Cancer       Date:  2017-12-15       Impact factor: 7.396

6.  Lentivirus-mediated bifunctional cell labeling for in vivo melanoma study.

Authors:  Chi-Ping Day; John Carter; Carrie Bonomi; Dominic Esposito; Bruce Crise; Betty Ortiz-Conde; Melinda Hollingshead; Glenn Merlino
Journal:  Pigment Cell Melanoma Res       Date:  2009-01-19       Impact factor: 4.693

7.  ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence.

Authors:  Linan Ha; Takeshi Ichikawa; Miriam Anver; Ross Dickins; Scott Lowe; Norman E Sharpless; Paul Krimpenfort; Ronald A Depinho; Dorothy C Bennett; Elena V Sviderskaya; Glenn Merlino
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-19       Impact factor: 11.205

8.  Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function.

Authors:  Charles Keller; Benjamin R Arenkiel; Cheryl M Coffin; Nabeel El-Bardeesy; Ronald A DePinho; Mario R Capecchi
Journal:  Genes Dev       Date:  2004-10-15       Impact factor: 11.361

9.  MyoD and E-protein heterodimers switch rhabdomyosarcoma cells from an arrested myoblast phase to a differentiated state.

Authors:  Zhihong Yang; Kyle L MacQuarrie; Erwin Analau; Ashlee E Tyler; F Jeffery Dilworth; Yi Cao; Scott J Diede; Stephen J Tapscott
Journal:  Genes Dev       Date:  2009-03-15       Impact factor: 11.361

10.  Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts.

Authors:  Karen Fernandez; Yelda Serinagaoglu; Sue Hammond; Laura T Martin; Paul T Martin
Journal:  Am J Pathol       Date:  2009-12-17       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.